about
Comparison of Echocardiographic Measures in a Hispanic/Latino Population With the 2005 and 2015 American Society of Echocardiography Reference Limits (The Echocardiographic Study of Latinos).ARTS: automated randomization of multiple traits for study design.Hypoxia-induced pulmonary hypertension in type 2 diabetic mice.Enhanced risk profiling of implanted defibrillator shocks with circulating SCN5A mRNA splicing variants: a pilot trial.Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell diseaseMechanistic insights and characterization of sickle cell disease-associated cardiomyopathyComplex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells.Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell DiseaseEndotoxin- and mechanical stress-induced epigenetic changes in the regulation of the nicotinamide phosphoribosyltransferase promoter.Association of circulating transcriptomic profiles with mortality in sickle cell disease.Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets.Capsaicin-induced Ca2+ signaling is enhanced via upregulated TRPV1 channels in pulmonary artery smooth muscle cells from patients with idiopathic PAH.Cardiac Regeneration in the Human Left Ventricle After CorMatrix Implantation.Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function: Results From ECHO-SOL (Echocardiographic Study of Latinos).Anti-inflammatory properties of amniotic membrane patch following pericardiectomy for constrictive pericarditisHow prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension.LPS Induced Acute Lung Injury Involves the NF-κB-mediated Downregulation of SOX18.Correction: Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients.Dysregulated Nox4 ubiquitination contributes to redox imbalance and age-related severity of acute lung injury.Hyper-activation of pp60Src limits nitric oxide signaling by increasing asymmetric dimethylarginine levels during acute lung injury.Endothelial HIF-2α Contributes to Severe Pulmonary Hypertension by Inducing Endothelial-to-Mesenchymal Transition.Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension.Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung.Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension.Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.Divergent Changes of p53 in Pulmonary Arterial Endothelial and Smooth Muscle Cells Involved in the Development of Pulmonary HypertensionRight ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertensionGenetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysisPathogenic Role of mTORC1 and mTORC2 in Pulmonary HypertensionNew cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension.Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular DiseaseGender Difference in Damage-Mediated Signaling Contributes to Pulmonary Arterial HypertensionThe associations between anthropometric measurements and left ventricular structure and function: the Echo-SOL StudyMendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertensionEXPRESS: Surfing the Right Ventricular Pressure Waveform: Methods to assess Global, Systolic and Diastolic RV Function from a Clinical Right Heart CatheterizationAmerican Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney diseaseImaging assessment of cardioprotection mediated by a dodecafluoropentane oxygen-carrier administered during myocardial infarctionEnd points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settingsEnd points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
P50
Q30366671-10655E57-7F83-49CE-8F99-E31C3F1CCEDDQ33641988-C788AC1A-29DC-4FB6-89F4-C6B7E70F6D44Q33738536-4CA977B8-D705-41F0-91E9-213ED319F049Q33896741-2FEBB6B4-1C9C-4D88-AA7C-409963E40C2FQ34872759-E17D84FA-1299-4EC8-AB3F-5BD13B8F60E9Q35078958-C5C599BE-9238-4234-A9AD-09463331A3B2Q36017200-1E5B6F81-DC5F-4895-8B10-94B76F78CD95Q36135607-038ED3BF-69D0-47F4-B74B-353D0691EC75Q37555411-A97F835A-E43C-4D0D-A780-AFD2CCB97053Q38857629-385D361D-763B-4B44-8EA0-656564745211Q39040020-53B54F1E-93A0-4C97-9599-F967286AF217Q39162656-F849AD9A-6F2F-4BB4-833F-B1F1FCA6CCD4Q40080649-4075A6EC-B083-4BCA-8513-1DE869BBBBD5Q40546014-6D92A6B2-3E2E-4C3A-BD2C-85D4D4D5A59EQ42327778-97871E79-215B-4BAD-A38C-A8397B61024FQ42357125-14D491B7-2D53-4EB8-B459-B6A100EA3C1FQ45072273-DB3CEF1F-BE1C-4618-B34A-7FF6D3510053Q45891700-57D12B2E-677F-4015-85CD-45D330F10E20Q46436039-A29A24A9-0748-456D-979A-8CF995C8035EQ47100484-4A768879-482D-4A28-81CE-54A63EBC65D3Q47598587-DA4E9234-A1AB-41DF-BF37-6164C3619D34Q47688780-41FC5A95-ACFE-4F9B-8641-48B3E6BAF096Q50110443-023C4713-133E-419D-B8C6-05969FF0149FQ52312349-21F9C34B-2081-4AD0-AF56-A925ED3A7B65Q52590098-349E86AB-E219-43F6-9E1B-EFA5C345F2B0Q55330316-358320A3-372C-4B91-A526-5D1193EBA2BAQ57784529-B06148C1-4877-41AE-9520-9AAFB1705FCAQ58733985-B0AC511B-FDD7-4603-BD6C-69C96A86F1D5Q60460101-130C451E-7E02-40E7-800C-0BE0CFA7922BQ60923995-1B47FFE7-EA2C-4CA6-8021-36D572D96EB6Q64911746-FF740482-8AE7-43E5-9568-F243D7AF7FDAQ90956181-A44AF1AF-5F13-4622-AECB-FA347909A780Q91085172-96128715-7606-480C-8F52-464C9E2D1F8FQ91169209-7B75830A-E761-4024-A928-98017BE6BD5AQ91343649-FAD72CE2-73FB-408A-8BA6-9F5DEAF8EF78Q91589824-60C48A6E-96DF-4931-8CF0-696DCF0714B0Q91639061-7D8E1876-DE74-48F8-8064-FD6C9E6FEA06Q91647388-3F38A3DC-2E9C-444B-9BCD-551EEE7DFC83Q91757346-2CC923FB-E4E6-4780-BB44-3B2CD2E96BF5Q91757352-48129B5C-3CCB-4B48-AFB9-A66773A58479
P50
description
researcher
@en
wetenschapper
@nl
name
Ankit A Desai
@en
Ankit A Desai
@nl
type
label
Ankit A Desai
@en
Ankit A Desai
@nl
prefLabel
Ankit A Desai
@en
Ankit A Desai
@nl
P31
P496
0000-0001-6427-616X